Ignite Creation Date:
2024-10-25 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06528301
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-25
Brief Title:
A Phase 1 Study of UB-VV111 With and Without Rapamycin in RelapsedRefractory CD19 B-cell Malignancies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Multicenter Open-label Study of UB-VV111 in Combination With Rapamycin in RelapsedRefractory RR CD19 B-cell Malignancies
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111 The study will enroll patients with relapsedrefractory large B-cell lymphoma LBCL and chronic lymphocytic leukemia CLL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None